{"contentid": 487972, "importid": NaN, "name": "Super-blockbuster Biktarvy backed by more positive data", "introduction": "Gilead Sciences has announced new, long-term data from open-label extensions of two Phase III studies of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).", "content": "<p>Gilead Sciences (Nasdaq: GILD) has announced new, long-term data from open-label extensions of two Phase III studies of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).</p>\n<p>Data from Study 1489 and Study 1490 show the sustained efficacy and safety profile of Biktarvy, in the treatment of HIV-1 in treatment-na&iuml;ve adults.</p>\n<p>Presented at the 28th Conference on Retroviruses and Opportunistic Infections, the results also show that there was no treatment-emergent resistance for those treated with the product.</p>\n<p>Facing declining sales in its hepatitis C business, Gilead has invested heavily in Biktarvy, a three-in-one complete regimen for the treatment of HIV-1 infection.</p>\n<p>Swiftly reaching blockbuster status following its first approval in 2018, analysts have forecast that peak annual sales for Biktarvy could exceed $11 billion in coming years.</p>\n<p>In 2020, the product generated sales of $7.26 billion, a rise of 53% on the year before.</p>\n<h2>Long-term data encouraging</h2>\n<p>In both studies, up to 98% of participants who initiated treatment with Biktarvy and remained in the study achieved and maintained an undetectable viral load.</p>\n<p>High efficacy and durable viral suppression were also observed in participants who switched to Biktarvy from a dolutegravir-containing triple therapy for the 48-week open-label extension periods.</p>\n<p>Virology senior vice president Diana Brainard said: &ldquo;Gilead is committed to developing innovative HIV treatments, like Biktarvy, that help to address the unmet needs of people living with HIV today, including achieving and maintaining an undetectable viral load over the long-term.&rdquo;</p>\n<p>She added: &ldquo;These data reinforce that Biktarvy provides durable viral suppression, strong efficacy and a high barrier to resistance in both adults that are new to HIV therapy and those replacing their existing treatment.&rdquo;</p>", "date": "2021-03-08 11:44:00", "meta_title": NaN, "meta_keywords": "Biktarvy, data, Gilead, long-term, studies, open-label, treatment, Super-blockbuster, backed, positive, alafenamide, bictegravir/emtricitabine/tenofovir", "meta_description": "Gilead Sciences has announced new, long-term data from open-label extensions of two Phase III studies of Biktarvy (bictegravir/emtricitabine/tenofovir alafenami", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-08 11:44:22", "updated": "2021-03-08 11:57:56", "access": NaN, "url": "https://www.thepharmaletter.com/article/super-blockbuster-biktarvy-backed-by-more-positive-data", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "gilead-big.jpg", "image2id": "gilead-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Anti-virals, Infectious diseases", "topic_tag": "Conferences, Drug Trial, Research", "geography_tag": "USA", "company_tag": "Gilead Sciences", "drug_tag": "Biktarvy", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-08 11:44:00"}